Physician profile
William Borders
NPI 1063077261
$1,232.68
in general payments reported to CMS, 2019-2025
22 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.75 · 2023: $276 · 2024: $583 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.86 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $131.20 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $117.73 | 2022-2025 | |
| Amgen INC. | $108.59 | 2024-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $75.64 | 2023-2025 | Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $66.88 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $60.55 | 2023-2025 | |
| Astellas Pharma US INC | $57.39 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $56.22 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $35.59 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $31.75 | 2024 | Spravato |
| Inspire Medical Systems, INC. | $27.69 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $27.01 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $24.76 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2024 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $17.71 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $16.57 | 2024 | |
| Gilead Sciences, INC. | $16.19 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.27 | 2023 | |
| Lundbeck LLC | $15.09 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2023 | Xifaxan |
| Axsome Therapeutics, INC. | $12.89 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Borders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.